Answers are grounded in this paper and cite their sources.
Schizophrenia is a debilitating mental disorder whose nature is still a conundrum, and for which treatments are still not fully satisfactory. While numerous alternative pathogenic processes are discussed, a common end path where they converge, may still not be excluded. Accumulating evidence strongly suggests that schizophrenia symptoms arise from a progredient functional dysconnectivity in multiple neuronal circuits of the brain. The search for key mechanisms responsible for dysconnectivity identified oligodendroglia and their myelination of neuronal projections as potential key pathogenic base. It was suggested that this leads to synaptic dysfunctions in networks resulting in a decline and disengagement of otherwise highly convergent information processing. A key pathological process, emerging now, may be a developmentally emerging or induced disturbance in dynamic sphingolipid regulation within oligodendrocytes. This will lead to a disruption in the dynamics of cerebral network myelination. Resulting unsystematic dyscoordination of conduction speed and lack of information convergence will then blur network efficacy and distort information processing. Here, we review the evidence suggesting the brain sphingolipid system as a potential nodal point in the pathogenesis of schizophrenia. New evidence suggests components of the sphingolipid system as a druggable target for a better therapy of schizophrenia.
No takes yet. Share an insight, caveat, or question.
MÜLLER et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: